ClinicalTrials.gg
RecruitingNCT05820893Updated Nov 19, 2026

Resistant Potato Starch to Alleviate GWI

A Phase 2 interventional study of Resistant Potato Starch in Gulf War Illness, sponsored by VA Office of Research and Development. Recruiting at 1 site in United States. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by VA Office of Research and Development · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Persian Gulf Syndrome with a site in United States — 9 open to participants now, 9 under way, 1 of them phase 3. Persian Gulf Syndrome · United States.

Planned enrollment
17th of 31
52 · median 53
Started
2025
with 2 others
Phase 2
5 of 41
2 open now
Registered
36th of 41
by date
Lead sponsor
3 of 41
VA Office of Research and Development

Among the 41 studies in Persian Gulf Syndrome with a site in United States, this one is the 17th largest by planned enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 in phase 2, and was the 36th registered.

Persian Gulf Syndrome

41 studies on the registry are indexed under Persian Gulf Syndrome; 9 are open to participants now.

Browse Persian Gulf Syndrome studies →

Open to participants now

9 of the 41 studies in Persian Gulf Syndrome with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Persian Gulf Syndrome studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Persian Gulf Syndrome with a site in United States, or all of them as a file.
02

Study summary

Gulf War Illness (GWI) affects an estimated 25-32% of the over 700,000 coalition troops deployed to the Persian Gulf as part of the First Gulf War. GWI causes a range of pain, fatigue, gastrointestinal, skin, neurologic, and respiratory symptoms. New treatments to reduce GWI-associated morbidity are critically needed. Research suggests a role for the gastrointestinal microbiome in mediating health, including through impacting metabolism and immunity. The disruption of this microbiome plays a role in multiple diseases, and preliminary data suggest that Veterans with GWI have altered gut microbiota. The investigators will evaluate the effectiveness of a dietary fiber prebiotic supplement intervention on improving the quality of life of Veterans with GWI.

Read the detailed description

Background: Despite medical advancements, Gulf War illness (GWI) treatment remains a major challenge. Gulf war veterans with GWI can experience acute or chronic disorders of diarrhea, nausea, joint pain, muscle pain, general fatigue, sleep problems skin rashes, wheezing, persistent cough, dizziness and headaches. It is estimated 25-32% of the over 700,000 coalition troops deployed report symptoms consistent with GWI, 47% of whom experience gut-related symptoms. Longitudinal studies have shown little to no overall improvement in symptoms over time. Currently there are very limited treatment courses for GWI and even fewer for gut-related symptoms leading to the advisory committee on GWIs call for research leading to effective treatments improving the health of GWVs. Studies have shown that the gut is comprised of diverse bacteria that plays a critical role in the health of an individual. Comprised gut microbiota can lead to serious consequences such as GWI. There is thus a critical need to identify a new treatment that is safe, effective with minimal adverse effect to reduce GWI-associated morbidity. Prebiotics are such an example. Prebiotics are natural fibers derived from carbohydrates and can be beneficial to gut microbiota (good bacterial in the gut). Resistant starches (RS) are dietary fiber prebiotics found naturally in many foods including potatoes, plantains, and legumes. In addition to being highly accessible, RS have been shown to be well tolerated with few adverse reactions. While no studies of RS exist in GWI patients, a meta-analysis of RS in IBD has shown RS to be an effective treatment in both animal and clinical studies where improvements in clinical remission and reduced mucosal damage were found. Furthermore, numerous studies have found RS to reduce inflammation in murine models of colonic inflammation and to modify the intestinal microbiota and associated metabolome in mice and swine.

Objectives: The investigators hypothesize those randomized to the RS prebiotic group will experience a reduction in GWI symptoms following the completion of the trial. The investigators also hypothesize the prebiotic group will have increased concentrations of SCFAs and SCFA-producing bacteria in the gut compared to those in the control group.

Methods: This is a phase II randomized clinical trial in Veterans with GWI experiencing gut symptoms. Subjects will be randomized to either taking a RS prebiotic daily for 4 weeks or to the control group (maintenance of normal diet). Subjects will provide stool and serum samples as well as complete a series of health history and dietary questionnaires.

03

Conditions studied

  • Gulf War Illness

Browse trials for

Keywords

  • Persian Gulf Syndrome
  • Gulf War Illness
  • Veterans
  • Gastrointestinal Microbiome
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to provide informed written consent
  2. Willing to comply with all study procedures and be available for the duration of the study (including providing stool samples)
  3. Meeting the modified Kansas GWI case definition* with gut symptoms endorsed
  4. Deployed to Persian Gulf during Operations Desert Storm or Desert Shield56.Aged 50-85 years old

    • Moderate to severe GWI symptoms lasting at least 6 months in a minimum of three of the six symptom domains (one of which must be fatigue). The symptom domains are:

      • Pain (joint pain, muscle pain)
      • Gastrointestinal (diarrhea, nausea, vomiting, cramping)
      • Respiratory (persistent cough, wheezing)
      • Skin (rashes)
      • Fatigue (sleep problems, fatigue)
      • Neurologic (memory problems, headaches, dizziness, mood changes)

Exclusion criteria

Exclusion Criteria:

  1. A Known SARS-CoV-2 infection in the last 60 days and/or with a diagnosis of post-acute sequelae of COVID-19 (PASC, sometimes called long COVID) defined as COVID-19 symptoms lasting for greater than 6 months.
  2. Subjects identified as, or appearing to, lack consent capacity
  3. Alcohol abuse (greater than 14 drinks per week for men and 7 drinks per week for women)
  4. Use of drugs, biologics, or devices within 30 days prior to randomization.
  5. Individuals who are pregnant, lactating or planning on becoming pregnant during the study.
  6. Diagnosed inflammatory bowel disease, Crohn's disease, or Celiac's disease
  7. Uncontrolled/untreated hypothyroidism
  8. Previous gastrointestinal surgery (colorectal surgery, gastric bypass, intestinal resection)
  9. Systemic antibiotics in the last 30 days
  10. Fecal microbiota transplant in the last 30 days
  11. Active dysphagia
  12. Allergies to any of the ingredients in MSPrebiotic
  13. Use of immunomodulatory medications in the last 30 days
  14. Any other factor, condition, or medication not listed above the Investigators believe will affect the response in the gut or the interpretation of results.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Prebiotic arm

    Subjects will consume the RS prebiotic daily for 4 weeks. A dose escalation will be used with subjects taking 4g of the prebiotic for the first 4 days, 7g the next 3 days and the full dose of 10g on day 8.

    Drug: Resistant Potato Starch

  • No intervention
    Standard diet

    Subjects randomized to this arm will be asked to maintain their usual diet.

Interventions

  • MSPrebiotic (MSPrebiotic Inc, Carberry, Manitoba, Canada). MSPrebiotic is an unmodified resistant starch derived from potatoes (Solanar tuberosum). It consists of 20% amylose and 80% amylopectin forming granules the stomach and small intestine are unable to digest allowing for absorption in the colon. MSPrebiotic is consumed by mixing 10g into cold or room temperature foods or beverages; it is not to be heated. Participants will be instructed to take MSPrebiotic 2 or more hours before or after consuming any medications.

    Also known as: MSPrebiotic

06

What researchers measure

Primary outcomes

  1. Changes from baseline to the end of the study period in the composition of the gut microbiome

    The gut microbiome will be assessed using next generation sequencing (shotgun metagenomics)

    Time frame: 2 years

  2. Changes from baseline to the end of the study period in the concentration of short-chain fatty acids and other metabolites identified in the gut microbiome

    The metabolites in the gut will be identified through next-generation sequencing technology and both targeted and untargeted metabolomics.

    Time frame: 2 years

Secondary outcomes

  1. Improvement in quality of life

    Quality of life will be assessed using the Gastrointestinal Quality of Life Index (GIQLI) questionnaire from baseline to the end of the study period.

    Time frame: 2 years

  2. Changes in GWI symptoms over the study period

    A GWI symptoms assessment tool will be used to determine changes in symptoms from baseline to the end of the study period.

    Time frame: 2 years

  3. Changes in overall health over the study period

    The Veterans RAND-36 (VR-36) questionnaire will be used to determine changes in overall health and associated quality of life over the study period.

    Time frame: 2 years

  4. Tolerability of the probiotic defined as discontinuation due to adverse events during the study period

    Assess the tolerability of orally consuming MSPrebiotic by determining the frequency of withdraws from the study due to the occurrence of adverse events.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • William S. Middleton Memorial Veterans Hospital, Madison, WI
    Madison, Wisconsin 53705-2254, United States
    Recruiting
    • Nasia Safdar, MD PhD · ContactNasia.Safdar@va.gov · 608-280-7007
    • Nasia Safdar, MD PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — A BioProject will be created with NCBI and sequencing data will be shared there with a limited, deidentified set of metadata from participants. Additional data can be obtained from the research team with permissions.

Supporting information: Study protocol, Analytic code

Time frame: 3 years

Access criteria: Written requests for access to the data will be accepted. Data and documentation will be available under a data use agreement (DUA) that provides a commitment to use data for research purposes only, not to attempt to identify participants, to secure data using appropriate computer technology, and to destroy/return data after analyses are complete.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Jun 2027, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2023
First posted
Apr 20, 2023
StartActual
Feb 3, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers
1 update, last Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Minor edits only
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05820893
Responsible party
Sponsor
First posted
Apr 20, 2023
Start date
Feb 3, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Nasia Safdar, MD PhD
Contact
Nasia.Safdar@va.gov
(608) 280-7007
Julie A Keating, PhD
Contact
julie.keating@va.gov
(608) 256-1901 ext. 12542
Nasia Safdar, MD PhD
principal investigator · William S. Middleton Memorial Veterans Hospital, Madison, WI

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Resistant Potato Starch

Start the discussion